Kodiak Sciences to Present at Upcoming Conferences

Rhea-AI Summary

Kodiak Sciences Inc. (Nasdaq: KOD) has announced its participation in two upcoming virtual investor conferences. The first is the Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:00 PM PT, and the second is the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 1:40 PM PT. Both presentations will be available via live webcast on the company's website, with replays offered afterward. Kodiak focuses on developing therapeutics for retinal diseases, leveraging its ABC Platform™.

PALO ALTO, Calif., May 20, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences:

• Jefferies Virtual Healthcare Conference on Thursday, June 3 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time)
• Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8 at 1:40 p.m. Pacific Time (4:40 p.m. Eastern Time)

A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.

About Kodiak Sciences Inc.

Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.

Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

View original content:http://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-upcoming-conferences-301296566.html

SOURCE Kodiak Sciences Inc.

FAQ

When will Kodiak Sciences present at the Jefferies Virtual Healthcare Conference?

Kodiak Sciences will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:00 PM Pacific Time.

What is the date for Kodiak Sciences' presentation at the Goldman Sachs Conference?

Kodiak Sciences will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 1:40 PM Pacific Time.

Where can I watch the Kodiak Sciences presentations?

The presentations can be watched live via webcast on Kodiak Sciences' website in the 'Events and Presentations' section.

What is Kodiak Sciences' focus in biopharmaceuticals?

Kodiak Sciences focuses on researching and developing therapeutics for high prevalence retinal diseases.

What is the ticker symbol for Kodiak Sciences?

The ticker symbol for Kodiak Sciences is KOD.